Specifically, mutations causing over-activation of the mitogen-activated protein kinase (MAPK) signaling pathway are found in more than 70% of papillary thyroid cancers and include BRAF oncogene activation, RAS mutations and RET proto-oncogene rearrangement [4]. This evidence concerns the gene BRAF and thyroid gland papillary carcinoma.